chest pain News
-
Oleum, Sulfur Trioxide, and Sulfuric Acid Vol. VIII Issue 12
These three very corrosive chemicals are closely related. Oleum is cloudy, oily, fuming liquid or sometimes a solid which releases sulfur trioxide in contact with air as in a spill. This sulfur trioxide reacts quickly with any air moisture producing a fine sulfuric acid mist. Inhalation at low concentrations for a short period irritates the nose, throat, and lungs. Prolonged exposure or higher ...
-
XyloCor Therapeutics Doses Patients in Phase 1/2 Trial Evaluating Novel Gene Therapy XC001 in Refractory Angina
XyloCor Therapeutics today announced it has successfully dosed the first two patients in the EXACT Trial, a Phase 1/2 dose escalation trial evaluating the safety, tolerability and efficacy of its lead candidate XC001 in patients with refractory angina. The trial will enroll patients who are not responding to medication and are unsuitable for coronary artery bypass graft or percutaneous coronary ...
-
XyloCor Therapeutics Achieves Target Enrollment in Phase 2 EXACT Study of XC001 Novel Gene Therapy for Ischemic Heart Disease
Positive Phase 1 results reported at the American Association for Thoracic Surgery (AATS) and the American Society of Gene and Cell Therapy (ASGCT) revealed XC001 is well tolerated at all dose levels Phase I data support XC001 therapeutic effect and potential dose response Topline Phase 2 data readout expected in February 2023 with interim results in the second half of this year XyloCor ...
-
Hemostemix Announces the Second Stem Cell Recipient Interview: One Week to no Chest Pain
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) is pleased to announce the second in its series of video interviews with ACP-01 recipients taped during August of 2021. With more than 300 patients treated compassionately with ACP-01 for ischemic cardiomyopathy, dilated cardiomyopathy, vascular dementia, COPD, and pulmonary hypertension, in this ...
-
Fusobacterium Infections Exposed in New Online Video
Today, the IAQ Video Network and Cochrane & Associates announced the release of another online video to help educate the public about issues that may impact their health. The latest educational video discusses Fusobacterium and infections caused by the bacteria. Fusobacterium are widely known human and animal pathogens and have a worldwide distribution. They are anaerobic, Gram negative ...
-
XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina
Independent Data Monitoring Committee authorized proceeding to Phase 2 at highest dose level tested following review of clinical safety data from the Phase 1 dose escalation Phase 2 clinical data readouts on safety and efficacy of XC001 anticipated in 2022 Company plans to commence study startup of XC001 as an adjunct to CABG in 2H21, and clinical studies in additional cardiovascular ...
-
XyloCor Therapeutics Announces Presentation of Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1/2 Study of XC001 Novel Gene Therapy for Refractory Angina at AATS and ASGCT
Data from the Phase 1 dose-escalation portion of the Phase 1/2 EXACT study demonstrate XC001 was well-tolerated at all dose levels tested; highest dose level evaluated selected for ongoing Phase 2 portion of the study – Preliminary efficacy data highlight XC001 potential for patients with refractory angina with no other treatment options – Treatment strategy is to use local ...
-
Elucid Raises $27 Million Series B Funding Round to Commercialize a New Paradigm in Heart Disease Diagnosis
BOSTON – June 22, 2022 – Elucid, a company developing a novel, non-invasive medical software to comprehensively characterize cardiovascular disease, announced the closing of a $27 Million Series B financing round. The round was led by an undisclosed strategic investor, with participation from Biovision Ventures, a new Europe-based fund, and existing investors, including MedTex ...
By Elucid
-
Accurate detection of Glutaraldehyde
The Glutaraldemeter 3 by PPM Technology is an easy-to-use, portable instrument that employs an electrochemical sensor to indicate levels of glutaraldehyde vapor in air. The instrument provides a rapid direct read-out of vapor levels on an LCD display, making it a useful screening tool to complement existing routine chemical glutaraldehyde monitoring techniques. User friendly and easy to ...
-
MagicTouch SCB Granted ‘Breakthrough Device Designation’ for the treatment of Small Coronary Artery Lesions.
Concept Medical Inc. (CMI) has been granted “Breakthrough Device Designation” from the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) for the MagicTouch SCB Sirolimus Coated Balloon Catheter, for the treatment of small coronary artery lesions in Coronary Artery Disease (CAD). The proposed indication for use includes “The ...
-
Elucid announces American Medical Association (AMA) instates CPT Code for Lipid-Rich Necrotic Core Quantification to Assess Atherosclerotic Plaque Stability
BOSTON – December 17, 2021 – Elucid, a Boston-based medical technology company harnessing scientific imaging and artificial intelligence to enable the precise diagnosis and treatment of the world’s leading cause of death announced a new CPT code unique to its Plaque IQ technology for CT angiography. Plaque composition, specifically lipid-rich necrotic core, has been identified ...
By Elucid
-
Acutus Medical completes enrollment in IDE trial with its AcQBlate FORCE Sensing Ablation System
Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced successful completion of patient enrollment in the company’s AcQForce™ Flutter Investigational Device Exemption (IDE) clinical trial which enrolled 110 patients at 21 sites globally. The AcQForce Flutter trial was designed to ...
-
Histoplasma Infection Risks for Workers and Vulnerable Populations in Puerto Rico
Histoplasmosis is the name of an infection caused by a fungus known as Histoplasma capsulatum. The fungus lives in the environment, particularly in soil or other materials that contain large amounts of bird or bat droppings. Outbreaks of histoplasmosis have been recorded in Puerto Rico, as well as in the Dominican Republic and other parts of the Caribbean. The Centers for Disease Control and ...
-
Taiho and Lung Therapeutics Enter Into an Exclusive License Agreement in Japan for LTI-01, Treatment for Loculated Pleural Effusions
Taiho Pharmaceutical Co., Ltd, (“Taiho”) and Lung Therapeutics, Inc. (“Lung Tx”) announced today an exclusive license agreement of LTI-01, a recombinant human single-chain urokinase plasminogen activator, currently under development by Lung Tx for loculated pleural effusions, for the territory of Japan. This press release features multimedia. View the full release here: ...
-
Histoplasmosis Infection Risks for Workers & Vulnerable Populations
ScienceNews published an article last year about the spread of three types of fungi that can cause serious lung diseases. One of these was Histoplasma which causes histoplasmosis, an infection once mainly found in the Midwest, but in more recent times infections have been recorded in at least 47 states. Histoplasma capsulatum lives in the environment, particularly in soil or other materials ...
-
Elucid Eyes Big Opportunity to Save Lives with Software Amidst Major Guideline Changes
BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software to enable cardiovascular disease detection, expects newly issued guidelines will be a catalyst for non-invasive image, revolutionizing the way patients with coronary artery disease are diagnosed and treated. In a highly anticipated document published online yesterday in Circulation and the Journal of ...
By Elucid
-
Breathing in Los Angeles and Pittsburgh can be hazardous for your health
One out of every 10 people in the United States lives in an area with unhealthy levels of all three types of air pollution tracked by the new American Lung Association State of the Air report - ozone, short-term particle pollution and year-round particle pollution. Published last week, the annual report shows that Los Angeles again is the city most affected by ozone and year-round particle ...
-
BioCardia Announces First Patient Treated in CardiAMP Cell Therapy Trial for Chronic Myocardial Ischemia
BioCardia, Inc. [Nasdaq: BCDA] a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the treatment of the first patient in its Phase III pivotal CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial for patients with no option chronic myocardial ischemia with refractory angina. These patients experience ...
-
Surprising scientific facts about love
On Valentine's Day some of us relish the opportunity to show our loved ones how much we appreciate them while for others the only thing to love about this day is pointing out how commercial and unnecessary it is. No matter which camp you fall into, there is no denying these 10 facts about love as proven by ...
-
XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease
Company closes additional $22.6 million in new financing Proceeds will fund initiation of new clinical trial for lead gene therapy candidate XC001 as adjunctive therapy for patients undergoing coronary artery bypass graft surgery XyloCor Therapeutics, a private clinical-stage biopharmaceutical company focused on the development of gene therapy for the significant unmet patient needs in ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you